Posted: May 5, 2009

Iron nanoparticle tools could detect pancreatic cancer earlier

(Nanowerk News) Pancreatic cancer has a devastatingly low survival rate (less than five percent after five years) because it is usually diagnosed at an advanced stage. The initial symptoms, such as pain, jaundice or weight loss, often do not allow the disease to be caught early enough for surgery and chemotherapy to be effective.
Emory researchers have created tools for early diagnosis of pancreatic cancer by attaching a molecule that binds specifically to pancreatic cancer cells to tiny nanoparticles made of iron oxide.
The iron makes the particles clearly visible under magnetic resonance imaging (MRI). Tested in mice with implanted human tumors, the particles can also be seen by scanning the mice with a specialized camera because the particles are studded with near infrared dyes.
The nanoparticles' properties are described in the May issue of the journal Gastroenterology (Molecular Imaging of Pancreatic Cancer in an Animal Model Using Targeted Multifunctional Nanoparticles).
The research was a collaboration between Lily Yang, MD, associate professor of surgery at Emory University School of Medicine, Hui Mao, PhD, associate professor of radiology at Emory, and Shuming Nie, PhD, a professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.
Additional contributions came from Charles Staley, MD, and William Wood, MD, both professors of surgery at Emory School of Medicine, and from Y. Andrew Wang of Ocean Nanotech LLC.
"This work is an early demonstration that nanoparticles can be developed to target pancreatic cancer, opening new opportunities in detecting and treating tumors of low survival rates," says Nie,
"We believe these nanoparticles could be useful tools for detection and localization before surgery, detection of tumor margins and metastases during surgery, and monitoring the response to therapy," Yang says. "We are working on multifunctional nanoparticles that could both detect pancreatic tumors by molecular imaging and deliver therapeutic agents in a targeted fashion."
The iron oxide particles have a core that is 10 nanometers in diameter, with a polymer coating. The molecule that allows the particles to discriminate between pancreatic cancer cells and healthy cells is an engineered small protein based on a natural protein found in humans, urokinase plasminogen activator (uPA), which binds to its receptor (uPAR) on cancer cells.
The authors note that uPA is useful in discriminating tumor cells from regular pancreas cells irritated by chronic pancreatitis, a challenging task in clinical diagnosis.
Particles coated with a fragment of uPA are taken up by pancreatic cancer cells and not by normal pancreatic tissues, they found. Tumor endothelial cells, which line blood vessels, also take up the particles, and a low signal is seen in liver and spleen.
Tumors as small as one millimeter across can be detected by MRI or optical imaging. The technology now needs to be refined so that it is ready to test in patients. Groups of patients that are at increased risk of pancreatic cancer, such as those with inherited cancer risk factors, chronic pancreatitis or new-onset diabetes, could benefit.
Source: Emory University
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: